Anamorelin HCI is a novel, orally active selective ghrelin receptor agonist being developed to treat anorexia, cachexia, or unintended weight loss in NSCLC patients. Helsinn said ghrelin is
KU is the US specialty generic pharmaceuticals subsidiary of biopharmaceuticals firm UCB. The acquisition creates a key player in drug industry. The combined company generated pro-forma revenues of
Bristol-Myers Squibb planned to use the drug a single agent to treat previously untreated patients, specifically those with BRAF V600 mutation positive unresectable or metastatic melanoma. The company
The facility, which will be built next to the company’s two existing plants, will have 180,000 liters of capacity. The company said in a filing that it expects
The company placed 9.1 million shares with existing institutional shareholders at 225.00 pence per share. hVIVO will use the net proceeds of sale to progress PrEP-001 to Phase
Idarucizumab is indicated to reverse the anticoagulant effects of dabigatran etexilate during emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding. It binds specifically to
Sinclair said the sale creates an aesthetics firm, with high gross margins recorded in full year 2015. The company’s pro-forma net cash position of £82m will allow it
The approval was based on data the Phase III coBRIM study, which demonstrated that Cotellic plus Zelboraf helped people with previously untreated BRAF V600 mutation-positive advanced melanoma live
Teva agreed to pay Heptares $10m upfront, and potentially up to $400m in payments tied to achieving research, development, and commercialization milestones. Heptares is also eligible to receive
The drug’s earlier indication was for the second-line treatment of NSCLC. The data supporting the expanded label was generated by the Phase 3 Profile 1014 study. The study
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.